Evidence map›Paper›PMID 21079786›Full record

ArticlePloS one2010

The structural complexity of the human BORIS gene in gametogenesis and cancer.

Elena M Pugacheva, Teruhiko Suzuki, Svetlana D Pack, Natsuki Kosaka-Suzuki, Jeongheon Yoon, Alexander A Vostrov, Eugene Barsov, Alexander V Strunnikov, Herbert C Morse, Dmitri Loukinov and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 68 citations in OpenAlex.

  1. Loss of miR-122 promotes cell migration and poor prognosis in triple-negative breast cancer treated by neoadjuvant chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. CTCF and CTCFL in cancer.Current opinion in genetics & development · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Targeting CTCFL/BORIS for the immunotherapy of cancer.Cancer immunology, immunotherapy : CII · 2018
    Review
  16. BORIS: a key regulator of cancer stemness.Cancer cell international · 2018
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Elena M PugachevaLaboratory of Immunopathology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, Maryland, United States of America. epugacheva@niaid.nih.gov
Teruhiko Suzuki
Svetlana D Pack
Natsuki Kosaka-Suzuki
Jeongheon Yoon
Alexander A Vostrov
Eugene Barsov
Alexander V Strunnikov
Herbert C Morse
Dmitri Loukinov
Victor Lobanenkov
National Institutes of Health · USNational Institute of Allergy and Infectious Diseases · USScience Applications International Corporation (United States) · USState University of New York · US

Funding

Lymphomas And Retroviral PathogenesisZIAAI000858 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MORSE, HERBERT · 2009 to 2018
$5.3M
Intramural NIH HHS
6 · The paper itself

Abstract

backgroundBORIS/CTCFL is a paralogue of CTCF, the major epigenetic regulator of vertebrate genomes. BORIS is normally expressed only in germ cells but is aberrantly activated in numerous cancers. While recent studies demonstrated that BORIS is a transcriptional activator of testis-specific genes, little is generally known about its biological and molecular functions. METHODOLOGY/PRINCIPAL

findingsHere we show that BORIS is expressed as 23 isoforms in germline and cancer cells. The isoforms are comprised of alternative N- and C-termini combined with varying numbers of zinc fingers (ZF) in the DNA binding domain. The patterns of BORIS isoform expression are distinct in germ and cancer cells. Isoform expression is activated by downregulation of CTCF, upregulated by reduction in CpG methylation caused by inactivation of DNMT1 or DNMT3b, and repressed by activation of p53. Studies of ectopically expressed isoforms showed that all are translated and localized to the nucleus. Using the testis-specific cerebroside sulfotransferase (CST) promoter and the IGF2/H19 imprinting control region (ICR), it was shown that binding of BORIS isoforms to DNA targets in vitro is methylation-sensitive and depends on the number and specific composition of ZF. The ability to bind target DNA and the presence of a specific long amino terminus (N258) in different isoforms are necessary and sufficient to activate CST transcription. Comparative sequence analyses revealed an evolutionary burst in mammals with strong conservation of BORIS isoproteins among primates.

conclusionsThe extensive repertoire of spliced BORIS variants in humans that confer distinct DNA binding and transcriptional activation properties, and their differential patterns of expression among germ cells and neoplastic cells suggest that the gene is involved in a range of functionally important aspects of both normal gametogenesis and cancer development. In addition, a burst in isoform diversification may be evolutionarily tied to unique aspects of primate speciation.

Indexed as

Alternative SplicingAmino Acid SequenceAnimalsBase SequenceCCCTC-Binding FactorDNA-Binding ProteinsDNA MethylationFemaleGametogenesisGene Expression RegulationHCT116 CellsHEK293 CellsHumansK562 CellsLuminescent ProteinsMaleCCCTC-Binding FactorCTCFL protein, humanCTCF protein, humanDNA-Binding ProteinsLuminescent ProteinsProtein IsoformsRepressor ProteinsTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID21079786
PMCPMC2975627
OpenAlexW2031642253

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.